&lt;p&gt;Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers&lt;/p&gt;

Yoshida, Kazuhide; Okamoto, Masato; Sasaki, Jun; Kuroda, Chika; Ishida, Haruka; Ueda, Katsuya; Okano, Satomi; Ideta, Hirokazu; Kamanaka, Takayuki; Sobajima, Atsushi; Takizawa, Takashi; Kito, Munehisa; Aoki, Katsumi; Uemura, Takeshi; Haniu, Hisao; Kato, Hiroyuki; Saito, Naoto

doi:10.2147/ott.s198421

Cited by 24 publications

(23 citation statements)

References 33 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been reported that a high level of PD-L1 predicts a reduced 5-year event-free survival in patients with OS, and is correlated with early metastasis [24,26]. We did not observe a significant difference in survival rates between PD-1-positive and -negative cases or PD-L1-positive and -negative cases.…”

Section: Discussioncontrasting

confidence: 46%

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma

2020

View full text Add to dashboard Cite

Recent data have suggested that PD-1 and PD-L1 are involved in osteosarcoma (OS) pathogenesis; however, their contributions are not well-established. Here, the PD-1/PD-L1 expression was evaluated in (OS) cases. Preoperative needle biopsy specimens were obtained from 16 patients with OS. Immunostaining for CD4, CD8, PD-1, and PD-L1 was performed on pathological specimens. Clinical parameters, including age, tumor size, preoperative alkaline phosphatase (ALP) level, standardized uptake value (SUV)-max level, and survival rate, were compared between PD-1/PD-L1-positive and -negative groups. CD4-, CD8-, PD-1-, and PD-L1-positive rates among all specimens were 75%, 75%, 18.7%, and 62.5%, respectively. The rates of co-expression of CD4 and CD8 with PD-L1 were 56.2% and 50%, respectively. Tumors were significantly larger in PD-L1-negative cases than in PD-L1-positive cases. Age, size and ALP and SUV-max levels did not differ significantly between PD-1/PD-L1-positive and -negative cases. The 3-year survival rates did not differ significantly between PD-1-positive and -negative cases or between PD-L1-positive and -negative cases. However, the occurrence of cancer-related events, including recurrence, metastasis, and death was associated with the PD-1-negative and PD-L1-positive status. The PD-1/PD-L1 checkpoint is likely involved in the immune microenvironment in OS and may be involved in the occurrence of cancer-related events.

show abstract

Section: Discussioncontrasting

confidence: 46%

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma

2020

View full text Add to dashboard Cite

show abstract

“…The existing poor prognosis of OS can be traced to tumor progression and recurrence, and this problem has resulted in a low 5-year survival rate for people diagnosed with bone cancer. 4 To improve the survival outcome of patients with OS, it is crucial to explore the molecular mechanism of OS progression.…”

Section: Introductionmentioning

confidence: 99%

hsa_circ_0085539 Promotes Osteosarcoma Progression by Regulating miR-526b-5p and SERP1

Liu

Wang

et al. 2020

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

This study aimed to expand the competing endogenous RNA network in osteosarcoma (OS) involving hsa_circ_0085539 and its downstream target miR-526b-5p. The expression levels of circ_0085539, miR-526b-5p, and stress-associated endoplasmic reticulum protein 1 (SERP1) mRNA in OS tissues and cells were detected and analyzed by qRT-PCR. After that, the interrelationships between these three genetic materials were validated with a luciferase reporter assay system. The effect of the circ_0085539/miR-526b-5p/SERP1 axis on OS cell malignancy phenotypes was further assessed using in vitro assays, including cell counting kit-8 (CCK-8) assays, colony foci formation assays, wound-healing migration assays, and transwell invasion assays. To determine the function of circ_0085539 on OS tumor growth in vivo , a xenograft formation assay was performed. In OS tissues and cells, the expression of circ_0085539 and SERP1 was upregulated, while that of miR-526b-5p was downregulated. After experimental analyses, it was found that silencing circ_0085539 inhibited the aggression of OS in vivo and in vitro . Mechanistic investigations also revealed that circ_0085539 could sponge miR-526b-5p and that miR526b-5p could directly target SERP1. The cytological experiments in vitro demonstrated that miR-526b-5p could restore the effect of circ_0085539 in terms of promoting OS malignancy phenotypes by suppressing SERP1. Overall, the present study validated that hsa_circ_0085539 could promote the progression of OS by regulating miR-526b-5p/SERP1.

show abstract

“…In the clinical setting, PD-L1 expression is known to correlate with bad prognosis [ 79 ], and patients with higher levels of T-cell activation markers show good prognosis [ 80 ]. However, the phase 2 clinical trial using the anti-PD-1 antibody (Pembrolizumab) with sarcoma patients resulted in only one of the 22 patients with osteosarcoma having an objective response [ 81 ].…”

Section: Cancer Immune Therapy and Cancer Immunoeditingmentioning

confidence: 99%

A Review of T-Cell Related Therapy for Osteosarcoma

Yoshida

Okamoto

Aoki

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Osteosarcoma is one of the most common primary malignant tumors of bone. The combination of chemotherapy and surgery makes the prognosis better than before, but therapy has not dramatically improved over the last three decades. This is partially because of the lack of a novel specialized drug for osteosarcoma, which is known as a tumor with heterogeneity. On the other hand, immunotherapy has been one of the most widely used strategies for many cancers over the last ten years. The therapies related to T-cell response, such as immune checkpoint inhibitor and chimeric antigen receptor T-cell therapy, are well-known options for some cancers. In this review, we offer the accumulated knowledge of T-cell-related immunotherapy for osteosarcoma, and discuss the future of the therapy.

show abstract

<p>Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers</p>

Cited by 24 publications

References 33 publications

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma

hsa_circ_0085539 Promotes Osteosarcoma Progression by Regulating miR-526b-5p and SERP1

A Review of T-Cell Related Therapy for Osteosarcoma

Contact Info

Product

Resources

About